Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Nilotinib is a second-generation tyrosine kinase inhibitor that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib versus imatinib (ENESTnd). Apart from this registration study, very few data a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Levato, Luciano, D’Adda, Mariella, Stagno, Fabio, Tiribelli, Mario, Salvucci, Marzia, Fava, Carmen, Martino, Bruno, Cedrone, Michele, Bocchia, Monica, Trabacchi, Elena, Cavazzini, Francesco, Usala, Emilio, Rossi, Antonella Russo, Bochicchio, Maria Teresa, Soverini, Simona, Alimena, Giuliana, Cavo, Michele, Pane, Fabrizio, Martinelli, Giovanni, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800682/
https://ncbi.nlm.nih.gov/pubmed/26113419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.129221
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars